文献速递炎症性肠病

在未接受过生物制剂治疗的患者中,起始联合治疗相比单药治疗与炎症性肠病相关并发症风险降低相关:一项基于人群的队列研究

Upfront Combination Therapy, Compared With Monotherapy, for Patients Not Previously Treated With a Biologic Agent Associates With Reduced Risk of Inflammatory Bowel Disease-related Complications in a Population-based Cohort Study.
PubMed 文献 · Clin Gastroenterol Hepatol · 2018-11-15

该研究基于2001至2016年曼尼托巴炎症性肠病流行病学数据库,纳入开始抗TNF治疗的克罗恩病(n=852)和溃疡性结肠炎(n=303)患者,比较联合免疫调节剂与单药治疗的有效性。结果显示,联合治疗与克罗恩病患者治疗无效风险显著降低相关(aHR 0.62,95%CI 0.49-0.79),但在溃疡性结肠炎患者中无显著关联(aHR 0.82,95%CI 0.56-1.20)。

要点

  • 克罗恩病患者起始联合免疫调节剂与抗TNF治疗与治疗无效风险降低相关(aHR 0.62)。
  • 溃疡性结肠炎患者中联合治疗与治疗无效的关联无统计学意义(aHR 0.82)。
  • 克罗恩病患者联合治疗与IBD相关住院和更换抗TNF药物风险降低相关。

核心结论

  • 在真实世界IBD患者数据库分析中,起始联合免疫调节剂与抗TNF治疗与克罗恩病患者治疗无效可能性降低相关,但与溃疡性结肠炎患者无显著关联。

研究设计与样本

  • 基于人群的队列研究,数据来自曼尼托巴炎症性肠病流行病学数据库,纳入2001年至2016年开始抗TNF治疗的克罗恩病(n=852)和溃疡性结肠炎(n=303)患者。
  • 开始抗TNF治疗时新用和/或继续使用免疫调节剂者视为联合治疗。
  • 主要结局为治疗无效,定义为抗TNF治疗期间或停药后90天内发生IBD相关住院、肠切除、使用糖皮质激素或更换抗TNF药物。
  • 采用Cox比例风险模型评估免疫调节剂联用与治疗无效的关联。

主要发现

  • 克罗恩病患者中,联合治疗与治疗无效可能性显著降低相关(aHR 0.62;95%CI 0.49-0.79)。
  • 溃疡性结肠炎患者中,联合治疗与治疗无效的关联无统计学意义(aHR 0.82;95%CI 0.56-1.20)。
  • 克罗恩病患者中,联合治疗与首次IBD相关住院时间延长相关(aHR 0.53;95%CI 0.36-0.80),与更换抗TNF药物风险降低相关(aHR 0.63;95%CI 0.41-0.97)。
  • 克罗恩病患者中,联合治疗与IBD相关手术(aHR 0.76;95%CI 0.51-1.12)及新发或复发使用糖皮质激素(aHR 0.75;95%CI 0.55-1.04)无显著关联。

关键数值与推荐

  • 克罗恩病治疗无效:联合治疗aHR 0.62(95%CI 0.49-0.79)。
  • 溃疡性结肠炎治疗无效:联合治疗aHR 0.82(95%CI 0.56-1.20)。
  • 克罗恩病首次IBD相关住院:联合治疗aHR 0.53(95%CI 0.36-0.80)。
  • 克罗恩病更换抗TNF药物:联合治疗aHR 0.63(95%CI 0.41-0.97)。
  • 克罗恩病IBD相关手术:联合治疗aHR 0.76(95%CI 0.51-1.12);新发或复发使用糖皮质激素:aHR 0.75(95%CI 0.55-1.04)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Although guidelines recommend inclusion of immune modulators in anti-tumor necrosis factor (TNF) initiation therapy for Crohn's disease (CD) or ulcerative colitis (UC), there are limited data on the incremental effectiveness of this treatment strategy from the real world. METHODS: We collected data from the Manitoba Inflammatory Bowel Disease (IBD) Epidemiology database on persons with CD (n=852) or UC (n=303), from 2001 through 2016, who began treatment with a TNF antagonist. New and/or continuing users of immunomodulators at the time anti-TNF therapy began were considered recipients of combination therapy. The main outcome was treatment ineffectiveness (IBD-related hospitalization, intestinal resection, corticosteroid use, or change of anti-TNF agent) during TNF antagonist-based therapy or within 90 days after the anti-TNF agent was discontinued. We used Cox proportional hazards models to assess the association between concomitant use of immunomodulators and treatment ineffectiveness. RESULTS: In patients with CD, combination therapy was associated with a significant decrease in likelihood of treatment ineffectiveness (adjusted hazard ratio [aHR] for ineffectiveness, 0.62; 95% CI, 0.49-0.79). However, this association was not significant in patients with UC (aHR, 0.82; 95% CI, 0.56-1.20). In patients with CD, combination therapy was also associated with increased time to first IBD-related hospitalization (aHR 0.53; 95% CI, 0.36-0.80) and switching anti-TNF agents (aHR, 0.63; 95% CI, 0.41-0.97), but not associated with IBD-related surgery (aHR, 0.76; 95% CI, 0.51-1.12) or new or recurrent use of corticosteroids (aHR, 0.75; 95% CI, 0.55-1.04). CONCLUSION: In an analysis of a database of real-world patients with IBD, we associated initiation therapy with a combination immune modulators and anti-TNF agents with a decreased likelihood of treatment ineffectiveness for patients with CD but not UC.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Targownik LE, Benchimol EI, Bernstein CN, et al. Upfront Combination Therapy, Compared With Monotherapy, for Patients Not Previously Treated With a Biologic Agent Associates With Reduced Risk of Inflammatory Bowel Disease-related Complications in a Population-based Cohort Study. Clin Gastroenterol Hepatol. 2018. PMID: 30448599. doi:10.1016/j.cgh.2018.11.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。